EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial

Jorge E Rojas-Rivera iD, Fernando Caravaca-Fontán iD, Anne-Els van de Logt, Angel Sevillano, Amir Shabaka iD, Ana Ávila, Cristina Rabasco, Virginia Cabello, Alberto Ortiz iD, Luis F Quintana iD, Marian Goicoechea, Montserrat Diaz iD und 4 weitere

Clinical Kidney Journal · 01.09.2025 · 18 (9)

DOI: 10.1093/ckj/sfaf256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 13.08.2025. Verfasst von Jorge E Rojas-Rivera und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Hospital Universitario Fundación Jiménez Díaz & Current Visiting Research Scholar, The Ohio State Universi…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with primary membranous nephropathy may progress to advanced chronic kidney disease despite immunosuppressive therapy (IST). Prediction of treatment response based on early and combined assessment of several standard clinical markers could improve risk stratification for progression, allowing timely individualization of treatment, which can optimize clinical outcomes and safety.

Methods

In this post hoc exploratory analysis of the STARMEN trial, we evaluated if combined baseline data, and IST-induced early changes in standard clinical markers predicted clinical remission at 2 years. The 2-year primary outcome was complete (CR) or partial remission (PR). The secondary outcome was CR. Additionally, we described kidney function outcomes. Standard clinical markers were incorporated into statistical modeling by logistic regression. Predictive performance was assessed by receiver operating characteristic curve analysis.

Results

The best multivariate model excluding immunosuppression to predict complete or PR at 2 years, included 3-month 24-h proteinuria, serum creatinine and immunological response [area under the curve (AUC) 0.87, 95% confidence interval (CI) 0.76–0.94, efficiency 87%]. For CR at 2 years, the best model included the same clinical markers at 6 months, but predictive performance was lower (AUC 0.74, 95% CI 0.62–0.85, efficiency 70%).

Conclusions

In the STARMEN cohort, a multivariable model that included 24-h proteinuria, serum creatinine and immunological response status at 3 months after initiation of IST predicted clinical remission at 2 years with significantly better predictive performance than baseline data or each clinical marker assessed separately.

Schlagwörter

Stichwörter der Autor:innen

anti-PLA2R antibodiesclinical remissionnephrotic syndromepredictive modelsprimary membranous nephropathy

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, Hospital Universitario Fundación Jiménez Díaz & Current Visiting Research Scholar, The Ohio State University - Wexner Medical Center, Columbus, OH, USA.
  • Universidad Autónoma de Madrid, Madrid, Spain.
  • Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Nephrology, Radboud Institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Nephrology, Hospital Universitario Doctor Peset, Valencia, Spain.

ORCID-Profile: Jorge E Rojas-Rivera, Fernando Caravaca-Fontán, Amir Shabaka, Alberto Ortiz, Luis F Quintana, Montserrat Diaz, Pierre Ronco, Manuel Praga

Förderung

  • Instituto de Salud Carlos III
  • Fondo Europeo de Desarrollo Regional

Zitieren

APA

Rojas-Rivera, J. E., Caravaca-Fontán, F., van de Logt, A. E., Sevillano, A., Shabaka, A., Ávila, A., Rabasco, C., Cabello, V., Ortiz, A., Quintana, L. F., Goicoechea, M., Diaz, M., Ronco, P., Wetzels, J., Fernández-Juárez, G., & Praga, M. (2025). Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial. Clinical Kidney Journal, 18(9). https://doi.org/10.1093/ckj/sfaf256

Vancouver

Rojas-Rivera JE, Caravaca-Fontán F, van de Logt AE, Sevillano A, Shabaka A, Ávila A, et al. Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial. Clinical Kidney Journal. 2025;18(9). doi:10.1093/ckj/sfaf256

BibTeX
@article{RojasRivera2025,
  author = {Rojas-Rivera, Jorge E and Caravaca-Fontán, Fernando and van de Logt, Anne-Els and Sevillano, Angel and Shabaka, Amir and Ávila, Ana and Rabasco, Cristina and Cabello, Virginia and Ortiz, Alberto and Quintana, Luis F and Goicoechea, Marian and Diaz, Montserrat and Ronco, Pierre and Wetzels, Jack and Fernández-Juárez, Gema and Praga, Manuel},
  title = {Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {9},
  doi = {10.1093/ckj/sfaf256}
}
Kostenlos starten →